logo
Embrace private healthcare to fix the NHS, says former Boots boss

Embrace private healthcare to fix the NHS, says former Boots boss

Yahooa day ago

The former boss of Boots has urged the Government to embrace private medical care to fix the NHS, as he backed plans to inject tens of billions of pounds into the struggling health service.
Sebastian James, the former Bullingdon Club member who endorsed Labour last year, said Rachel Reeves is right to propose a £30bn funding boost for the NHS as part of her upcoming spending review.
However, he urged ministers to use the cash to 'grasp the nettle of private provision', as he said that easing pressure on cash-strapped NHS hospitals was key to reducing waiting lists.
Mr James is already working with the NHS to help outsource cataract surgeries as the chief executive of European eye clinic chain Veonet, which runs the SpaMedica business in the UK.
But he said Wes Streeting, the Health Secretary, must go further and faster on working with the private sector after waiting lists recently rose for the first time in seven months.
The backlog now stands at 7.42m, according to data released for the end of March.
'We need radical change that can be achieved by releasing a measurable sum of money,' Mr James, the son of the hereditary peer the 5th Baron Northbourne, told The Telegraph.
'We need a more commercial approach. We have to grasp the nettle of private provision. We understand people's hesitation, but we want to see what's best for the patient.'
The suggestion echoes ideas put forward by Richard Tice, Reform UK's deputy leader.
He has called for the NHS to buy millions more appointments from the independent sector to help address waiting lists, claiming it could help to clear the appointment backlog within two years.
This would go further than the Government's current pledge to offer up to a million extra appointments in private hospitals.
Yet such ideas are controversial as they will stoke fears of creeping privatisation of the NHS and raise concerns about potential profiteering.
Mr James said: 'There are questions about private companies making money. But it's all about how do you square that?
'There are two key things. One, it will still be free at the point of use. And two, the price will be cheaper than what is offered by the public healthcare system.'
Mr James has already held talks with Whitehall officials about his plans for the NHS and he said the Chancellor is right to unleash a significant one-off sum.
'You should borrow to pay for it,' said Mr James, suggesting that £20bn or £30bn would barely move the dial when it comes to the country's £2.8 trillion debt pile.
However, it comes at a time when the Chancellor is already facing a struggle to balance the books.
Ms Reeves will this week deliver her spending review, which is widely expected to unlock an extra £30bn for the NHS over a three-year period.
That will be at the expense of other public services, as she is also plotting real-terms cuts to day-to-day spending across many Whitehall departments.
Such pressures have emerged because of the Chancellor's fiscal rules, which prevent her from borrowing to fund day-day-day spending.
However, Mr James believes that borrowing to fix the waiting list crisis would do far greater good than harm.
He said that SpaMedica's role in providing eye services for the NHS should be a blueprint for ministers to work from, as the company claims to have helped cut waiting times for cataract surgery from 18 months to two weeks since Covid.
It now provides around 70pc of eye care referrals from the NHS, and last year helped to restore the sight of around 200,000 patients.
While it has helped to cut waiting times, SpaMedica is one of many private cataract clinics facing claims of profiteering after they allegedly inflated costs for procedures.
A leaked document from the Health Department, first reported by The Sunday Times, alleged that SpaMedica classed its patients as 'higher complexity', which led to procedures being more expensive than they needed to be.
Campaigners point to the fact that SpaMedica's profits rose from £63.9m to £71.8m in its last financial year, which they say is proof of the company taking the taxpayer for a ride.
SpaMedica has denied any wrongdoing.
However, such allegations reflect the fierce debate surrounding privatisation of the NHS, with many households uncomfortable with the prospect of independent providers making a profit while providing medical services, even if they are free for patients.
Mr James, who ran Boots from 2018 to 2024, is adamant that ministers must ignore such complaints if they are to have any hope of reducing waiting lists.
'We have cut waiting times down from 18 months to two to three weeks,' said Mr James. 'We have eaten away our waiting list.'
This is particularly key for Sir Keir Starmer, who has pledged that 92pc of NHS patients will get an appointment within 18 weeks by the end of the current parliament in 2029.
Ultimately, Mr James argues that private healthcare must be embraced because it is far more efficient than the NHS.
He said that SpaMedica clinics carry out more than 20 cataract surgeries a day, which is almost double that of NHS hospitals.
The fees are also cheaper, he said, as each cataract operation costs SpaMedica £980, compared to around £1,400 on the NHS.
'We've shown that we can do it in our industry, but we need to broaden it out,' he said. 'We could take it area by area, whether that be knee replacements or treating melanomas.
'By working with private healthcare providers, the solution is to save the NHS money.
'We understand people's hesitation, but we want to see what's best for the patient. We're not talking about eradicating the NHS, it's about a partnership.'
Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hair Cortisone Predicts Metabolic Syndrome in Young Adults
Hair Cortisone Predicts Metabolic Syndrome in Young Adults

Medscape

timean hour ago

  • Medscape

Hair Cortisone Predicts Metabolic Syndrome in Young Adults

Long-term biological stress, measured using hair glucocorticoid levels, was strongly associated with the presence of metabolic syndrome (MetS) and its components such as waist circumference and triglycerides, with the association being particularly pronounced in younger adults for hair cortisone levels. METHODOLOGY: Researchers in the Netherlands conducted a cross-sectional study to investigate the relationship between hair glucocorticoid levels and the presence of MetS and its components in 1405 adult participants (median age, 49 years; 73.6% women) from the Netherlands Study of Depression and Anxiety cohort. Levels of hair glucocorticoids (cortisol and cortisone) were measured using liquid chromatography-tandem mass spectrometry. Outcomes were the presence of MetS and its individual components that included high-density lipoprotein cholesterol, fasting glucose, and triglyceride levels; diastolic blood pressure; and waist circumference. This study also assessed whether age (≤ 49 vs ≥ 50 years) modified the relationship between hair glucocorticoids and MetS. TAKEAWAY: Hair cortisol (odds ratio [OR], 1.27) and cortisone (OR, 1.32; P < .001 for both) levels were strongly associated with MetS, with the association between hair cortisone and MetS being significantly modified by age (OR, 0.78; P = .003). < .001 for both) levels were strongly associated with MetS, with the association between hair cortisone and MetS being significantly modified by age (OR, 0.78; = .003). The link between hair glucocorticoids and MetS was stronger in younger participants than in older ones for both hair cortisol (OR, 1.52 vs 1.20) and hair cortisone (OR, 1.95 vs 1.14). Hair cortisol and cortisone levels were positively correlated with waist circumference ( P < .001 for both) and triglyceride levels ( P < .025 for both); hair cortisol, but not cortisone, levels were also positively associated with diastolic blood pressure ( P = .034) and negatively associated with high-density lipoprotein cholesterol levels ( P = .035). IN PRACTICE: "In the future, [the study] findings can be used to identify individuals with increased cardiovascular risk," the authors wrote. SOURCE: This study was led by Susanne Kuckuck, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands. It was published online on June 03, 2025, in The Journal of Clinical Endocrinology & Metabolism . LIMITATIONS: The study population was predominantly Caucasian, which limited the generalisability of the findings to other populations and ethnic minorities. Information on diet was not collected; hence, the potential influence of nutritional factors on glucocorticoid metabolism could not be assessed. This study could not show whether elevated hair glucocorticoid levels caused MetS due to its cross-sectional design. DISCLOSURES: This study was supported by Stress in Action, a research project financially supported by the Dutch Research Council and the Dutch Ministry of Education, Culture and Science. The authors declared having no conflicts of interest.

Prevalence of Autoimmune Diseases Rose in UK Pregnancies
Prevalence of Autoimmune Diseases Rose in UK Pregnancies

Medscape

timean hour ago

  • Medscape

Prevalence of Autoimmune Diseases Rose in UK Pregnancies

Over the past two decades, the prevalence of autoimmune diseases among pregnant women in the UK has significantly increased, with psoriasis being the most common condition. The likelihood of diagnosis varied across sociodemographic factors, including age, ethnicity, and socioeconomic status. METHODOLOGY: Researchers conducted a UK population-based retrospective cohort study using routinely collected primary care data from Clinical Practice Research Datalink Gold and Aurum pregnancy registers. This study included 5,165,960 pregnancies in 2,831,472 women aged 15-49 years from 2000 to 2021, including 185,208 pregnancies in 100,655 women with a coded diagnosis of autoimmune disease. Researchers evaluated the prevalence trend, calculated annually for both overall and each of 17 autoimmune diseases, during pregnancy via diagnostic codes and analysed their associations with sociodemographic factors. TAKEAWAY: The overall prevalence of autoimmune diseases during pregnancy increased from 3.5% in 2000 to 4.7% in 2021; psoriasis was the most prevalent condition, followed by inflammatory bowel disease and rheumatoid arthritis between 2000 and 2010 and type 1 diabetes and inflammatory bowel disease in 2010-2021. The prevalence of most of the autoimmune diseases significantly increased between 2000 and 2021, with the steepest rise observed in Hashimoto's thyroiditis (+6.22%), coeliac disease (+6.20%), and alopecia areata (+4.75%). Women living in less deprived areas had higher odds of autoimmune diseases during pregnancy than those living in more deprived areas (adjusted odds ratio [aOR], 1.10; 95% CI, 1.07-1.14), and Black women had significantly lower odds than White women (aOR, 0.48; 95% CI, 0.45-0.51). Compared with women aged 15-20 years, those aged 21-30 years (aOR, 1.17; 95% CI, 1.14-1.20), 31-40 years (aOR, 1.50; 95% CI, 1.45-1.55), and 41-50 years (aOR, 1.75; 95% CI, 1.68-1.82) had increased odds of being diagnosed with autoimmune disease before pregnancy. IN PRACTICE: "This study gives a clear estimate of the burden of autoimmune diseases in pregnancy in the UK and the possible association with various demographic factors, and will help the process of improving maternity care for women with these health conditions," the authors wrote. SOURCE: This study was led by Megha Singh, PhD, Department of Applied Health Sciences, College of Medicine and Health, University of Birmingham, Birmingham, England. It was published online on June 02, 2025, in The Lancet Rheumatology . LIMITATIONS: This study did not include some rare autoimmune diseases like dermatomyositis. Although the use of primary care data reduced entry-level coding biases, improvements in recording practices over time might affect data quality and completeness, potentially affecting observed trends. Additionally, this study may have underestimated the prevalence of autoimmune diseases since most cases are diagnosed and managed in secondary care. DISCLOSURES: This study was supported by the Strategic Priority Fund "Tackling multimorbidity at scale" programme. One author initially worked at the University of Birmingham and later joined AstraZeneca and currently holds an honorary contract with the University of Birmingham.

L'Oréal to acquire majority stake in British skincare brand Medik8
L'Oréal to acquire majority stake in British skincare brand Medik8

Yahoo

timean hour ago

  • Yahoo

L'Oréal to acquire majority stake in British skincare brand Medik8

L'Oréal Group has signed an agreement to acquire a majority stake in UK-based skincare brand Medik8. Inflexion, a European mid-market private equity company, will retain a minority share post-transaction. The acquisition is a strategic move by L'Oréal to bolster its Luxe division with a brand that has a strong foundation in scientific research and innovation. Medik8's performance and potential for international expansion make it a valuable addition to L'Oréal's portfolio. L'Oréal will begin to consolidate Medik8's sales following the transaction's closure. The agreement grants L'Oréal rights to eventually acquire the remaining shares held by minority shareholders. L'Oréal LUXE president Cyril Chapuy stated: 'We are delighted to welcome Medik8 to the L'Oréal family. As a premium skincare range, with high levels of proven efficacy at an accessible price point, Medik8 perfectly complements our existing skincare portfolio. 'We share a strong belief in Medik8's global potential and are excited to embark on this journey together, to build a powerful and impactful brand presence worldwide.' Completion of the transaction is anticipated in the summer or early autumn of 2025, pending regulatory approvals. Founded by scientist Elliot Isaacs, Medik8 is known for its CSA Philosophy: Vitamin C plus Sunscreen by day, Vitamin A by night. Medik8's has expanded its omni-channel sales strategy to include major online and offline retailers in Europe and the US. Medik8 CEO Simon Coble stated: 'I am delighted to be joining forces with a company which shares our vision for the brand's future growth and whose core values align with our deep commitment to science, innovation and above all, results without compromise. I look forward to the next stage in Medik8's journey, as we work together to bring our innovative products to a wider audience.' "L'Oréal to acquire majority stake in British skincare brand Medik8" was originally created and published by Retail Insight Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store